靶向蛋白激酶用于癌症治疗：成功了吗？

Targeting protein kinases in cancer therapy: a success?

作者信息

Pearson Mark A, Fabbro Doriano

机构信息

Novartis Institutes for Biomedical Research Basel, Oncology, Novartis Pharma AG, WKL.125.4.16, CH-4002, Basel, Switzerland.

出版信息

Expert Rev Anticancer Ther. 2004 Dec;4(6):1113-24. doi: 10.1586/14737140.4.6.1113.

DOI:10.1586/14737140.4.6.1113

PMID:15606337

Abstract

The fundamental role of kinases in cancer progression has promoted the development of a plethora of therapeutic inhibitors. Despite the promise of effective treatment with little associated toxicity, the clinical experience with these agents has been mixed. This review will summarize recent advances made in the development of kinase inhibitors to highlight emerging issues and the strategies by which they being addressed.

摘要

激酶在癌症进展中的核心作用推动了大量治疗性抑制剂的研发。尽管有望实现有效治疗且几乎无相关毒性，但这些药物的临床应用效果参差不齐。本综述将总结激酶抑制剂研发方面的最新进展，以突出新出现的问题以及解决这些问题的策略。